#BEGIN_DRUGCARD DB00602

# AHFS_Codes:
8:08

# ATC_Codes:
P02CF01

# Absorption:
Moderately well absorbed. Improved absorption with high fat meal.

# Biotransformation:
Primarily hepatic. Ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days, with less than 1 % of the administered dose excreted in the urine.

# Brand_Mixtures:
Heel 170 Tab (Calcium Iodide + Fucus Vesiculosus + Ivermectin B1b + Silicon Dioxide)

# Brand_Names:
Ivermectin B1
Ivermectin-luminol
Mectizan
Sklice
Stromectol

# CAS_Registry_Number:
70288-86-7

# ChEBI_ID:
Not Available

# Chemical_Formula:
C95H146O28

# Chemical_IUPAC_Name:
(1'R,2R,4'S,5S,6R,8'R,12'S,13'S,20'R,21'R,24'S)-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-6-(propan-2-yl)-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-one; (1'R,2R,4'S,5S,6R,8'R,12'S,13'S,20'R,21'R,24'S)-6-[(2R)-butan-2-yl]-21',24'-dihydroxy-12'-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1^{4,8}.0^{20,24}]pentacosane]-10',14',16',22'-tetraen-2'-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2248882

# Description:
Ivermectin is a broad-spectrum anti-parasite medication. It was first marketed under the name Stromectol® and used against worms (except tapeworms), but, in 2012, it was approved for the topical treatment of head lice infestations in patients 6 months of age and older, and marketed under the name Sklice™ as well. Ivermectin is mainly used in humans in the treatment of onchocerciasis, but is also effective against other worm infestations (such as strongyloidiasis, ascariasis, trichuriasis and enterobiasis).

# Dosage_Forms:
Lotion	Topical
Tablet	Oral

# Drug_Category:
Anthelmintics
Antinematodal Agents
Antiprotozoal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
When administered with a high fat meal, the bioavailability is increased 2.5 times.

# GenBank_ID:
Not Available

# Generic_Name:
Ivermectin

# HET_ID:
Not Available

# Half_Life:
16 hours (also reported at 22-28 hours)

# InChI_Identifier:
InChI=1S/C48H74O14.C47H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38;1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3;11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b13-12+,27-15+,32-14+;12-11+,26-14+,31-13+/t25-,26+,28+,30+,31+,33-,34+,35+,36+,37+,38+,39+,40-,41+,42+,43-,44+,45-,47-,48-;25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m10/s1

# InChI_Key:
InChIKey=SPBDXSGPUHCETR-CVSKBELMSA-N

# Indication:
For the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite <i>Strongyloides stercoralis</i>. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite <i>Onchocerca volvulus</i>. Can be used to treat scabies caused by <i>Sarcoptes scabiei</i>.

# KEGG_Compound_ID:
C07970

# KEGG_Drug_ID:
D00804

# LIMS_Drug_ID:
602

# Mechanism_Of_Action:
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding causes an increase in the permeability of the cell membrane to chloride ions and results in hyperpolarization of the cell, leading to paralysis and death of the parasite. Ivermectin also is believed to act as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), thereby disrupting GABA-mediated central nervous system (CNS) neurosynaptic transmission. Ivermectin may also impair normal intrauterine development of O. volvulus microfilariae and may inhibit their release from the uteri of gravid female worms.

# Melting_Point:
155 °C

# Molecular_Weight_Avg:
1736.1589

# Molecular_Weight_Mono:
1735.000064088

# Organisms_Affected:
Head lice
Parasitic nematodes and other roundworms

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA450133

# Pharmacology:
Ivermectin is a semisynthetic, anthelminitic agent. It is an avermectin which a group of pentacyclic sixteen-membered lactone (i.e. a macrocyclic lactone disaccharide) derived from the soil bacterium Streptomyces avermitilis. Avermectins are potent anti-parasitic agents. Ivermectin is the most common avermectin. It is a broad spectrum antiparasitic drug for oral administration. It is sometimes used to treat human onchocerciasis (river blindness). It is the mixture of 22,23-dihydro-avermectin B1a (at least 90%) and 22,23-dihydro-avermectin B1b (less than 10%).

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00602

# Protein_Binding:
93%

# PubChem_Compound_ID:
46936176

# PubChem_Substance_ID:
46506810

# RxList_Link:
http://www.rxlist.com/cgi/generic3/ivermectin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01058

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CO[C@H]1C[C@@H](O[C@@H](C)[C@@H]1O)O[C@H]1[C@H](C)O[C@H](C[C@@H]1OC)O[C@H]1[C@@H](C)\C=C\C=C2/CO[C@@H]3[C@H](O)C(C)=C[C@@H](C(=O)O[C@H]4C[C@@H](C\C=C1/C)O[C@@]1(CC[C@H](C)[C@@H](C(C)C)O1)C4)[C@]23O.CC[C@@H](C)[C@H]1O[C@@]2(CC[C@@H]1C)O[C@@H]1C\C=C(C)\[C@@H](O[C@@H]3O[C@@H](C)[C@H](O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](OC)C4)[C@@H](OC)C3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O[C@@H](C1)C2)[C@]34O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
22,23-Dihydroxy-avermectin B
22,23-Dihyroavermectin B1
5-O-demethyl-22,23-dihydro-avermectin A1a

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub> = 29.5 mg/kg (Mouse, oral). LD<sub>50</sub> = 10 mg/kg (Rat, oral). Adverse effects include muscle or joint pain, dizziness, fever, headache, skin rash, fast heartbeat.

# Update_Date:
2013-05-07 12:08:15 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ivermectin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
15313134	Yates DM, Wolstenholme AJ: An ivermectin-sensitive glutamate-gated chloride channel subunit from Dirofilaria immitis. Int J Parasitol. 2004 Aug;34(9):1075-81.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
19336526	McCavera S, Rogers AT, Yates DM, Woods DJ, Wolstenholme AJ: An ivermectin-sensitive glutamate-gated chloride channel from the parasitic nematode Haemonchus contortus. Mol Pharmacol. 2009 Jun;75(6):1347-55. Epub 2009 Mar 31.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GLRA3

# Drug_Target_1_GenBank_ID_Gene:
AF017724

# Drug_Target_1_GenBank_ID_Protein:
3342792

# Drug_Target_1_GeneCard_ID:
GLRA3

# Drug_Target_1_Gene_Name:
GLRA3

# Drug_Target_1_Gene_Sequence:
>1398 bp
ATGGCCCACGTGAGACACTTTCGGACATTAGTTTCGGGATTTTACTTCTGGGAAGCAGCA
CTGTTACTCAGTTTGGTTGCCACAAAGGAAACAGACAGTGCAAGATCTCGAAGTGCTCCA
ATGTCACCTTCTGATTTTCTGGATAAATTAATGGGCAGGACATCAGGATATGATGCAAGA
ATCAGACCCAATTTTAAAGGCCCTCCAGTTAATGTCACATGCAACATATTCATCAACAGT
TTCGGCTCTATCGCAGAGACGACCATGGATTACAGAGTGAATATCTTTCTTCGTCAGAAA
TGGAATGATCCCCGCCTCGCGTACAGTGAATATCCTGACGACTCTTTAGACCTCGACCCC
TCCATGTTGGACTCCATTTGGAAACCTGATTTGTTCTTTGCCAATGAAAAGGGTGCCAAC
TTTCATGAAGTCACTACAGACAACAAATTGCTAAGAATTTTCAAAAATGGAAATGTTCTT
TATTCAATAAGATTAACATTAACACTTTCCTGTCCAATGGATCTCAAGAATTTTCCCATG
GATGTACAAACATGTATAATGCAACTGGAAAGCTTTGGGTACACAATGAATGATCTCATT
TTTGAATGGCAAGATGAGGCACCCGTACAAGTGGCAGAAGGACTCACTTTGCCCCAGTTT
CTGTTGAAAGAAGAAAAAGATTTACGATACTGCACTAAACATTACAATACAGGAAAGTTT
ACGTGTATAGAAGTGCGATTCCATCTGGAGCGACAAATGGGATACTATCTGATCCAGATG
TACATTCCCAGTCTCCTGATTGTTATTCTATCCTGGGTTTCGTTCTGGATCAACATGGAT
GCAGCACCGGCCAGGGTAGCTCTGGGGATAACCACCGTGCTAACGATGACTACACAGAGT
TCAGGATCACGAGCTTCCTTGCCAAAAGTTTCATATGTCAAAGCTATTGATATTTGGATG
GCAGTATGCCTCCTTTTTGTGTTTTCAGCACTTCTGGAGTATGCAGCTGTAAATTTTGTA
TCAAGACAACACAAAGAACTTCTGAGATTTCGACGAAAGAGAAAGAATAAGACAGAAGCT
TTTGCACTGGAGAAGTTTTACCGTTTCTCAGATATGGATGATGAGGTAAGGGAAAGCCGA
TTCAGCTTCACAGCCTATGGAATGGGACCATGTCTACAAGCAAAGGATGGCATGACTCCA
AAGGGCCCCAACCACCCTGTCCAGGTAATGCCAAAAAGTCCTGATGAAATGAGGAAGGTC
TTTATCGACCGGGCCAAGAAGATTGATACCATCTCCCGAGCCTGCTTCCCATTAGCTTTT
TTGATTTTTAATATTTTCTACTGGGTTATCTATAAAATTCTTAGGCATGAGGATATTCAT
CATCAGCAGCAAGATTAA

# Drug_Target_1_General_Function:
Involved in GABA-A receptor activity

# Drug_Target_1_General_References:
9677400	Nikolic Z, Laube B, Weber RG, Lichter P, Kioschis P, Poustka A, Mulhardt C, Becker CM: The human glycine receptor subunit alpha3. Glra3 gene structure, chromosomal localization, and functional characterization of alternative transcripts. J Biol Chem. 1998 Jul 31;273(31):19708-14.

# Drug_Target_1_HGNC_ID:
HGNC:4328

# Drug_Target_1_HPRD_ID:
02688

# Drug_Target_1_ID:
461

# Drug_Target_1_Locus:
4q33-q34

# Drug_Target_1_Molecular_Weight:
53801

# Drug_Target_1_Name:
Glycine receptor subunit alpha-3

# Drug_Target_1_Number_of_Residues:
464

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_1_Protein_Sequence:
>Glycine receptor subunit alpha-3 precursor
MAHVRHFRTLVSGFYFWEAALLLSLVATKETDSARSRSAPMSPSDFLDKLMGRTSGYDAR
IRPNFKGPPVNVTCNIFINSFGSIAETTMDYRVNIFLRQKWNDPRLAYSEYPDDSLDLDP
SMLDSIWKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLTLSCPMDLKNFPM
DVQTCIMQLESFGYTMNDLIFEWQDEAPVQVAEGLTLPQFLLKEEKDLRYCTKHYNTGKF
TCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQS
SGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRKNKTEA
FALEKFYRFSDMDDEVRESRFSFTAYGMGPCLQAKDGMTPKGPNHPVQVMPKSPDEMRKV
FIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHQQQD

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-33

# Drug_Target_1_Specific_Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing)

# Drug_Target_1_SwissProt_ID:
O75311

# Drug_Target_1_SwissProt_Name:
GLRA3_HUMAN

# Drug_Target_1_Synonyms:
Glycine receptor subunit alpha-3 precursor

# Drug_Target_1_Theoretical_pI:
8.51

# Drug_Target_1_Transmembrane_Regions:
253-279
286-303
315-341
434-451

# Drug_Target_2_Cellular_Location:
Membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
12421359	Feng XP, Hayashi J, Beech RN, Prichard RK: Study of the nematode putative GABA type-A receptor subunits: evidence for modulation by ivermectin. J Neurochem. 2002 Nov;83(4):870-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GABRB3

# Drug_Target_2_GenBank_ID_Gene:
M82919

# Drug_Target_2_GenBank_ID_Protein:
182925

# Drug_Target_2_GeneCard_ID:
GABRB3

# Drug_Target_2_Gene_Name:
GABRB3

# Drug_Target_2_Gene_Sequence:
>1422 bp
ATGTGGGGCCTTGCGGGAGGAAGGCTTTTCGGCATCTTCTCGGCCCCGGTGCTGGTGGCT
GTGGTGTGCTGCGCCCAGAGTGTGAACGATCCCGGGAACATGTCCTTTGTGAAGGAGACG
GTGGACAAGCTGTTGAAAGGCTACGACATTCGCCTAAGACCCGACTTCGGGGGTCCCCCG
GTCTGCGTGGGGATGAACATCGACATCGCCAGCATCGACATGGTTTCCGAAGTCAACATG
GATTATACCTTAACCATGTATTTTCAACAATATTGGAGAGATAAAAGGCTCGCCTATTCT
GGGATCCCTCTCAACCTCACGCTTGACAATCGAGTGGCTGACCAGCTATGGGTGCCCGAC
ACATATTTCTTAAATGACAAAAAGTCATTTGTGCATGGAGTGACAGTGAAAAACCGCATG
ATCCGTCTTCACCCTGATGGGACAGTGCTGTATGGGCTCAGAATCACCACGACAGCAGCA
TGCATGATGGACCTCAGGAGATACCCCCTGGACGAGCAGAACTGCACTCTGGAAATTGAA
AGCTATGGCTACACCACGGATGACATTGAGTTTTACTGGCGAGGCGGGGACAAGGCTGTT
ACCGGAGTGGAAAGGATTGAGCTCCCGCAGTTCTCCATCGTGGAGCACCGTCTGGTCTCG
AGGAATGTTGTCTTCGCCACAGGTGCCTATCCTCGACTGTCACTGAGCTTTCGGTTGAAG
AGGAACATTGGATACTTCATTCTTCAGACTTATATGCCCTCTATACTGATAACGATTCTG
TCGTGGGTGTCCTTCTGGATCAATTATGATGCATCTGCTGCTAGAGTTGCCCTCGGGATC
ACAACTGTGCTGACAATGACAACCATCAACACCCACCTTCGGGAGACCTTGCCCAAAATC
CCCTATGTCAAAGCCATTGACATGTACCTTATGGGCTGCTTCGTCTTTGTGTTCCTGGCC
CTTCTGGAGTATGCCTTTGTCAACTACATTTTCTTTGGAAGAGGCCCTCAAAGGCAGAAG
AAGCTTGCAGAAAAGACAGCCAAGGCAAAGAATGACCGTTCAAAGAGCGAAAGCAACCGG
GTGGATGCTCATGGAAATATTCTGTTGACATCGCTGGAAGTTCACAATGAAATGAATGAG
GTCTCAGGCGGCATTGGCGATACCAGGAATTCAGCAATATCCTTTGACAACTCAGGAATC
CAGTACAGGAAACAGAGCATGCCTCGAGAAGGGCATGGGCGATTCCTGGGGGACAGAAGC
CTCCCGCACAAGAAGACCCATCTACGGAGGAGGTCTTCACAGCTCAAAATTAAAATACCT
GATCTAACCGATGTGAATGCCATAGACAGATGGTCCAGGATCGTGTTTCCATTCACTTTT
TCTCTTTTCAACTTAGTTTACTGGCTGTACTATGTTAACTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1664410	Wagstaff J, Chaillet JR, Lalande M: The GABAA receptor beta 3 subunit gene: characterization of a human cDNA from chromosome 15q11q13 and mapping to a region of conserved synteny on mouse chromosome 7. Genomics. 1991 Dec;11(4):1071-8.
8382702	Kirkness EF, Fraser CM: A strong promoter element is located between alternative exons of a gene encoding the human gamma-aminobutyric acid-type A receptor beta 3 subunit (GABRB3). J Biol Chem. 1993 Feb 25;268(6):4420-8.

# Drug_Target_2_HGNC_ID:
HGNC:4083

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4099

# Drug_Target_2_Locus:
15q11.2-q12

# Drug_Target_2_Molecular_Weight:
54116

# Drug_Target_2_Name:
Gamma-aminobutyric-acid receptor subunit beta-3

# Drug_Target_2_Number_of_Residues:
473

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF02931	Neur_chan_LBD
PF02932	Neur_chan_memb

# Drug_Target_2_Protein_Sequence:
>Gamma-aminobutyric-acid receptor subunit beta-3
MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPP
VCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPD
TYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIE
SYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLK
RNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKI
PYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNR
VDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRS
LPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-25

# Drug_Target_2_Specific_Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel

# Drug_Target_2_SwissProt_ID:
P28472

# Drug_Target_2_SwissProt_Name:
GBRB3_HUMAN

# Drug_Target_2_Synonyms:
GABA(A
Gamma-aminobutyric-acid receptor subunit beta-3 precursor

# Drug_Target_2_Theoretical_pI:
9.41

# Drug_Target_2_Transmembrane_Regions:
246-267
271-293
305-327
451-472

#END_DRUGCARD DB00602
